0000000000393665

AUTHOR

S.r. Chandana

showing 2 related works from this author

Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or me…

2019

Oncologymedicine.medical_specialtyTemozolomideSurrogate endpointbusiness.industryCancerHematologyNeutropeniamedicine.diseaseChemotherapy regimenPoly (ADP-Ribose) Polymerase Inhibitorchemistry.chemical_compoundOncologychemistryResponse Evaluation Criteria in Solid TumorsInternal medicinemedicineRucaparibbusinessmedicine.drugAnnals of Oncology
researchProduct

530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pami…

2020

Oncologymedicine.medical_specialtyTemozolomidebusiness.industryLow doseLocally advancedHematologyPARP1OncologyInternal medicinemedicineBiomarker (medicine)businessmedicine.drugAnnals of Oncology
researchProduct